Search

The article reports on the unanimous vote from the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC) to recommend extending the use of Ixiaro, a Japanese encephalitis vaccine from Valneva, to children aged two months to 16 years old.

The article reports on the plan by the U.S. Advisory Committee on Immunization Practices to evaluate recommendations for the Japanese encephalitis vaccine in 2013.

The article reports on the availability of a vaccine against Japanese encephalitis in 2013.

The article discusses papers presented at the American Society of Tropical Medicine and Hygiene (ASTMH) meeting including Japanese encephalitis vaccination, diarrhea-related morbidity in children born to mothers with human immunodeficiency virus (HIV), and malaria resistance surveillance.

The article reports on the possible gap in the availability of the Japanese encephalitis vaccine for U.S. travelers in 2008. It is cited that the JE-Vax vaccine supply and the actual timing of licensure for the new inactivated cell culture-derived vaccine will lead to a supply gap. Production of the only licensed Japanese encephalitis vaccines in the U.S. has reportedly been stopped. As reported, Sanofi Pasteur has imposed restrictions on the vaccine in response to the potential supply shortage.